{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:13:12Z","timestamp":1791144792979,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Pulmonary arterial hypertension (PAH) is characterised by endothelial dysfunction and pathological vascular remodelling, resulting in the occlusion of pulmonary arteries and arterioles, right ventricular hypertrophy, and eventually fatal heart failure. Targeting the apelin receptor with the novel, G protein-biased peptide agonist, MM07, is hypothesised to reverse the developed symptoms of elevated right ventricular systolic pressure and right ventricular hypertrophy. Here, the effects of MM07 were compared with the clinical standard-of-care endothelin receptor antagonist macitentan.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Male Sprague-Dawley rats were randomised and treated with either normoxia\/saline, or Sugen\/hypoxia (SuHx) to induce an established model of PAH, before subsequent treatment with either saline, macitentan (30\u00a0mg\/kg), or MM07 (10\u00a0mg\/kg). Rats were then anaesthetised and catheterised for haemodynamic measurements, and tissues collected for histopathological assessment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The SuHx\/saline group presented with significant increases in right ventricular hypertrophy, right ventricular systolic pressure, and muscularization of pulmonary arteries compared to normoxic\/saline controls. Critically, MM07 was as at least as effective as macitentan in significantly reversing detrimental structural and haemodynamic changes after 4\u00a0weeks of treatment.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> These results support the development of G protein-biased apelin receptor agonists with improved pharmacokinetic profiles for use in human disease.<\/jats:p>","DOI":"10.3389\/fphar.2024.1369489","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:34:07Z","timestamp":1712637247000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The biased apelin receptor agonist, MM07, reverses Sugen\/hypoxia-induced pulmonary arterial hypertension as effectively as the endothelin antagonist macitentan"],"prefix":"10.3389","volume":"15","author":[{"given":"Thomas L.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duuamene","family":"Nyimanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoda E.","family":"Kuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Glen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet J.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"181","author":"Abe","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s44161-023-00347-2","article-title":"Current and future strategies for targeting the endothelin pathway in cardiovascular disease","volume":"2","author":"Abraham","year":"2023","journal-title":"Nat. Cardiovasc Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1172\/JCI43382","article-title":"Disruption of PPAR\u03b3\/\u03b2-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival","volume":"121","author":"Alastalo","year":"2011","journal-title":"J. Clin. Investigation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3390\/ijms19082289","article-title":"Factors associated with heritable pulmonary arterial hypertension exert convergent actions on the miR-130\/301-vascular matrix feedback loop","volume":"19","author":"Bertero","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1172\/JCI74773","article-title":"Systems-level regulation of microRNA networks by miR-130\/301 promotes pulmonary hypertension","volume":"124","author":"Bertero","year":"2014","journal-title":"J. Clin. Investigation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/HYPERTENSIONAHA.114.05099","article-title":"Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist","volume":"65","author":"Brame","year":"2015","journal-title":"Hypertension"},{"key":"B7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacbts.2018.01.013","article-title":"Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension","volume":"3","author":"Brash","year":"2018","journal-title":"Jacc-Basic Transl. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1161\/ATVBAHA.110.219980","article-title":"Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension","volume":"31","author":"Chandra","year":"2011","journal-title":"Arteriosclerosis Thrombosis Vasc. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"A1181","DOI":"10.1161\/JAHA.121.02496","article-title":"Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry","volume":"203","author":"Chang","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"170697","DOI":"10.1016\/j.peptides.2021.170697","article-title":"Apelin pathway in cardiovascular, kidney, and metabolic diseases: therapeutic role of apelin analogs and apelin receptor agonists","volume":"147","author":"de Oliveira","year":"2022","journal-title":"Peptides"},{"key":"B12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1183\/09031936.00204813","article-title":"SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction","volume":"44","author":"de Raaf","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s12350-016-0663-4","article-title":"Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416\/hypoxia rat model of severe pulmonary arterial hypertension","volume":"24","author":"Drozd","year":"2017","journal-title":"J. Nucl. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1046\/j.1471-4159.2001.00269.x","article-title":"Visualizing differences in ligand-induced beta-arrestin-GFP interactions and trafficking between three recently characterized G protein-coupled receptors","volume":"77","author":"Evans","year":"2001","journal-title":"J. Neurochem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"H2007","DOI":"10.1152\/ajpheart.00089.2009","article-title":"Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension","volume":"296","author":"Falcao-Pires","year":"2009","journal-title":"Am. J. Physiol. Heart. Circ. Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e129433","DOI":"10.1172\/JCI129433","article-title":"17\u03b2-Estradiol and estrogen receptor \u03b1 protect right ventricular function in pulmonary hypertension via BMPR2 and apelin","volume":"131","author":"Frump","year":"2021","journal-title":"J. Clin. Investigation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary-hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.regpep.2005.09.032","article-title":"Apelin: a new plasma marker of cardiopulmonary disease","volume":"33","author":"Goetze","year":"2006","journal-title":"Regul. Pept."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Graf","year":"2018","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1677\/ERC-07-0057","article-title":"Endothelins and hypoxia-inducible factor in cancer","volume":"14","author":"Grimshaw","year":"2007","journal-title":"Endocrine-Related Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/cells9061422","article-title":"The BMP receptor 2 in pulmonary arterial hypertension: when and where the animal model matches the patient","volume":"9","author":"Happ\u00e9","year":"2020","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.lfs.2013.12.215","article-title":"Inhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: potential roles of interleukin-6 and endothelin","volume":"118","author":"Hung","year":"2014","journal-title":"Life Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacc.2008.06.013","article-title":"Vascular effects of apelin in vivo in man","volume":"52","author":"Japp","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/CIRCULATIONAHA.109.911339","article-title":"Acute cardiovascular effects of apelin in humans potential role in patients with chronic heart failure","volume":"121","author":"Japp","year":"2010","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nm.3040","article-title":"An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension","volume":"19","author":"Kim","year":"2013","journal-title":"Nat. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.regpep.2004.10.019","article-title":"Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells","volume":"126","author":"Kleinz","year":"2005","journal-title":"Regul. Pept."},{"key":"B27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.109.134619","article-title":"Pyr(1) apelin-13 identified as the predominant apelin isoform in the human heart vasoactive mechanisms and inotropic action in disease","volume":"54","author":"Maguire","year":"2009","journal-title":"Hypertension"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2045894020947283","DOI":"10.1177\/2045894020947283","article-title":"Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats","volume":"10","author":"Mamazhakypov","year":"2020","journal-title":"Pulm. Circ."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/nyas.14123","article-title":"The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders","volume":"1455","author":"Marsault","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"18317","DOI":"10.1074\/jbc.M600606200","article-title":"The apelin receptor is coupled to G(i1) or G(i2) protein and is differentially desensitized by apelin fragments","volume":"281","author":"Masri","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2045893217741429","DOI":"10.1177\/2045893217741429","article-title":"Dual ETA\/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension","volume":"8","author":"Nadeau","year":"2017","journal-title":"Pulm. Circ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/CIRCRESAHA.111.300448","article-title":"Endothelin Axis is upregulated in human and rat right ventricular hypertrophy","volume":"112","author":"Nagendran","year":"2013","journal-title":"Circulation Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4103\/2045-8932.105031","article-title":"New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis","volume":"2","author":"Nicolls","year":"2012","journal-title":"Pulm Circ."},{"key":"B35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0378-1119(93)90495-o","article-title":"A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11","volume":"136","author":"O'Dowd","year":"1993","journal-title":"Gene"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/eurheartj\/ehr389","article-title":"Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1","volume":"33","author":"Pchejetski","year":"2012","journal-title":"Eur. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e93473","DOI":"10.1371\/journal.pone.0093473","article-title":"Apelin increases cardiac contractility via protein kinase C epsilon- and extracellular signal-regulated kinase-dependent mechanisms","volume":"9","author":"Perjes","year":"2014","journal-title":"Plos One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bcp.2016.07.018","article-title":"Cardiac action of the first G protein biased small molecule apelin agonist","volume":"116","author":"Read","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1124\/pr.119.017533","article-title":"International union of basic and clinical Pharmacology. CVII. Structure and Pharmacology of the apelin receptor with a recommendation that elabela\/toddler is a Second endogenous peptide ligand","volume":"71","author":"Read","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"588669","DOI":"10.3389\/fphar.2020.588669","article-title":"The G protein biased small molecule apelin agonist CMF-019 is disease modifying in endothelial cell apoptosis in vitro and induces vasodilatation without desensitisation in vivo","volume":"11","author":"Read","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"328","author":"Ruopp","year":"2022","journal-title":"Jama-Journal Am. Med. Assoc."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1172\/JCI69608","article-title":"Apelin is a positive regulator of ACE2 in failing hearts","volume":"123","author":"Sato","year":"2013","journal-title":"J. Clin. Investigation"},{"key":"B44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature11263","article-title":"APJ acts as a dual receptor in cardiac hypertrophy","volume":"488","author":"Scimia","year":"2012","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.7150\/ijbs.81436","article-title":"Apelin prevents and alleviates crystalline silica-induced pulmonary fibrosis via inhibiting transforming growth factor beta 1-triggered fibroblast activation","volume":"19","author":"Shen","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.lfs.2014.02.032","article-title":"Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro","volume":"118","author":"Star","year":"2014","journal-title":"Life Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/CIRCRESAHA.112.300623","article-title":"Unlooked-for significance of cardiac versus vascular effects of endothelin-1 in the pathophysiology of pulmonary arterial hypertension","volume":"112","author":"Taguchi","year":"2013","journal-title":"Circulation Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1096\/fj.00-0343com","article-title":"Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension","volume":"15","author":"Taraseviciene-Stewart","year":"2001","journal-title":"Faseb J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","article-title":"Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor","volume":"251","author":"Tatemoto","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"Bmj-British Med. J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"10742484231225310","DOI":"10.1177\/10742484231225310","article-title":"Sotatercept for pulmonary arterial hypertension in the inpatient setting","volume":"29","author":"Torbic","year":"2024","journal-title":"J. Cardiovasc Pharmacol. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tips.2015.06.002","article-title":"Apelin, Elabela\/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system","volume":"36","author":"Yang","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1161\/CIRCULATIONAHA.116.023218","article-title":"Elabela\/toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension","volume":"135","author":"Yang","year":"2017","journal-title":"Circulation"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/bph.14603","article-title":"A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension","volume":"176","author":"Yang","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/s0042-6822(02)00021-1","article-title":"Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJ","volume":"307","author":"Zhou","year":"2003","journal-title":"Virology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1369489\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:34:10Z","timestamp":1712637250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1369489\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":58,"alternative-id":["10.3389\/fphar.2024.1369489"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1369489","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"article-number":"1369489"}}